

Supplemental Materials

Table 1 Patients baseline characteristics of enrolled studies

Author	Subgroups	Age	Male	NYHA III-IV	Ejection fraction(%)	Complications
Martinez, G J¹		82±8.9	63	87(87%)	—	moderate to severe lung disease 12%; previous myocardial infarction 31%; cerebrovascular disease 28%; renal insufficiency 44%; atrial fibrillation 34%
Stabile, E²	single antiplatelet therapy	81.1 ±4.8	24	53	(<30%) 13.0%	diabetes 28.3%; hypertension 95.0%
	double antiplatelet therapy	80.2 ±5.7	16	54	(<30%) 11.6%	diabetes 25.0%; hypertension 95.0%
Omer, S³		77 ±9	19	19(100%)	51 ±17	diabetes 58%; hypertension 74%; COPD 21%; CAD 68%
Noble, S⁴		90.3 ±2.2	12	18(78.3%)	52.2 ±13.2	syncope 26.1%; angina 17.4%; diabetes 30.4%; hypertension 73.9%; CAD 65.2%; atrial fibrillation 39.1%
Walther, T⁵		82 ±6	89		—	
Latib, A⁶		80.5 ±6.9	49	75(67.6%)	53.5 ±12.5	CAD 39.6%; previous myocardial infarction 14.4%; diabetes 18.9%; cerebrovascular disease 14.4%; hypertension 70.3%; COPD 26.1%
Yamamoto, M⁷		91.6 ±1.9	5	17(65%)	51.3 ±12.3	previous heart failure 69%; previous myocardial infarction 19%; diabetes 23%; hypertension 73%; COPD 19%; chronic kidney disease 65%
Wendler, O⁸		80.6 ±7.1	571	(IV) 14.3%	(<30%) 5.6%	hypertension 68.9%; diabetes 28.6%; CAD 55.8%; congestive heart failure 28.4%; arrhythmia 31.7%; pulmonary disease 26.1%; renal insufficiency/failure 31.2%; stroke history 6.5%
Wendler, O⁹		80.3 ±5.7	117	101(84.2%)	(<30%) 2.5%	hypertension 86.7%; diabetes 30.0%; congestive heart failure 69.2%; arrhythmia 46.7%; pulmonary disease 35.0%; renal insufficiency 41.7%; stroke 15.8%;
Kempfert, J¹⁰		83.2 ±4.0	16	40(100%)	56.0 ±12.9	stroke 12.5%; chronic lung disease 22.5%;
Mieghem, N M¹¹		80.2 ±7.2	122	199(84%)	—	previous myocardial infarction 25.7%; CAD 56.1%; diabetes 26.2%; hypertension 59.1%; COPD 29.1%; atrial fibrillation 28.7%
Doss, M¹²		85 ±6	29	status 3.4 ±0.4	(<30%) 24%	respiratory dysfunction/COPD 33%; diabetes 29%; renal insufficiency 19%; CAD 43%; previous stroke 14%;arrhythmia 29%
Ducrocq, G¹³		81 ±8	105	196(98%)	50 ±15	hypertension 67%; diabetes 26%; renal failure 24%; cancer 27%; previous

						stroke 11%; COPD 30%; congestive heart failure 32%; CAD 57%
Ussia, G P¹⁴		80.9 ±6.1	80	124(68.5%)	51.3 ±13.1	diabetes 32.6%; CAD 53.0%; previous myocardial infarction 23.8%; stroke 4.4%; COPD 18.8%; renal insufficiency 28.7%; atrial fibrillation 12.7%
D'Onofrio, A¹⁵		81 ±6	198	419(83.1%)	52.4 ±13.6	hypertension 79.8%; diabetes 27.6%; COPD 34.3%; atrial fibrillation 23.6%; CAD 50.4%
Bosmans, J M¹⁶		83 ±6	46	259(79%)	55 ±14	atrial fibrillation 30%; CAD 58%; diabetes 27%; COPD 28%; renal failure 20%;
Hernaández-Antolín, R A¹⁷		83 ±6	28	58(76%)	62 ±13	CAD 50%; pulmonary disease 20%; cerebrovascular disease 8%; renal failure 18%
Johansson, M¹⁸		81 ±6	20	(IV) 30%	(<30%) 12.5%	COPD 32.5%; renal failure 5%; recent myocardial infarction 12.5%; CAD 62.5%
Lefèvre, T¹⁹		82.1 ±5.5	58	110(84.6%)	52.8 ±16.1	diabetes 31.5%; CAD 60.0%; myocardial infarction 20.8%; mitral valve disease 52.3%; atrial fibrillation 24.6%; AV Block 16.2%; renal failure 41.5%; pulmonary disease 41.5%; cancer 14.6%
Leon, M B²⁰		83.1 ±8.6	82	165(92.2%)	53.9 ±13.1	CAD 67.6%; previous myocardial infarction 18.6%; cerebral vascular disease 27.4%; COPD 41.3%; atrial fibrillation 32.9%;
Drews, T²¹	no previous heart surgery history	80 ±8.4	39	—	51 ±13.8	CAD 46%; diabetes 26%
	previous heart surgery history	75 ±10.6	22	—	43 ±14.6	CAD 85%; diabetes 30%
Attias, D²²		81 ±9	44	81(98%)	52 ±15	CAD 51%; renal failure 31%; severe COPD 33%; cancer 32%;
Ye, J²³		80.0 ±8.1	27	61(86.2%)	55.5 ±12.6	—
Guinot, P²⁴		81 ±8	50	82(91%)	51 ±14	hypertension 53%; atrial fibrillation 44%; diabetes 20%; cerebrovascular disease 38%; history of stroke 13%; CAD 66%; renal failure 48%; COPD 34%; history of cancer 32%
Avanzas, P²⁵		78.6 ±6.7	49	63(58.4%)	(<50%) 14.8%	diabetes 23.1%; hypertension 65.7%;
Kapadia, S R²⁶		81 ±6	12	18(100%)	46 ±17	COPD 44%; peripheral arterial disease 33%
Walther, T²⁷		78 [64—89]	10	mean status 3.2	(≤50%) 44%	chronic pulmonary disease 36%; neurological dysfunction 16%; renal failure 12%; recent myocardial infarction 8%
Webb, J G²⁸		82 ±7	30	45(90%)	(<50%) 24%	hypertension 62%; diabetes 24%; CAD 72%; severe lung disease 32%; cerebral ischemic event 12%; mitral regurgitation (moderate or severe) 48%;

Figure 1 Forest Plot Showing the Individual and Pooled Event Rates for different accesses





Figure 2 Forest Plot Showing the Individual and Pooled Event Rates for different valve choices




Figure 3 Forest Plot Showing the Individual and Pooled Event Rates for different risk score






Figure 4 Available Comparisons between TAVI and other treatment choices



References:

1. Martinez GJ, Seco M, Jaijee SK, Adams MR, Cartwright BL, Forrest P, Celermajer DS, Valley MP, Wilson MK, Ng MK. Introduction of an Interdisciplinary Heart Team-based Transcatheter Aortic Valve Implantation Program: Short and Mid-term Outcomes. *Intern Med J* 2014;44:876-883.
2. Stabile E, Pucciarelli A, Cota L, Sorropago G, Tesorio T, Salemme L, Popusoi G, Ambrosini V, Cioppa A, Agrusta M, Catapano D, Moscariello C, Trimarco B, Esposito G, Rubino P. SAT-TAVI (single antiplatelet therapy for TAVI) study: a pilot randomized study comparing double to single antiplatelet therapy for transcatheter aortic valve implantation. *Int J Cardiol* 2014;174:624-627.
3. Omer S, Kar B, Cornwell LD, Blaustein A, Levine GN, Ali N, Jneid H, Paniagua D, Atluri PV, Bechara CF, Koungias P, Ruma M, Preventza O, Bozkurt B, Carabello BA, Bakaeen FG. Early experience of a transcatheter aortic valve program at a Veterans Affairs facility. *JAMA Surg* 2013;148:1087-1093.
4. Noble S, Frangos E, Samaras N, Ellenberger C, Frangos C, Cikirikcioglu M, Bendjelid K, Frei A, Myers P, Licker M, Roffi M. Transcatheter aortic valve implantation in nonagenarians: effective and safe. *Eur J Intern Med* 2013;24:750-755.
5. Walther T, Thielmann M, Kempfert J, Schroefel H, Wimmer-Greinecker G, Treede H, Wahlers T, Wendler O. One-year multicentre outcomes of transapical aortic valve implantation using the SAPIEN XT valve: the PREVAIL transapical study. *Eur J Cardiothorac Surg* 2013;43:986-992.
6. Latib A, Maisano F, Bertoldi L, Giacomini A, Shannon J, Cioni M, Ielasi A, Figini F, Tagaki K, Franco A, Covello RD, Grimaldi A, Spagnolo P, Buchannan GL, Carlino M, Chieffo A, Montorfano M, Alfieri O, Colombo A. Transcatheter vs surgical aortic valve replacement in intermediate-surgical-risk patients with aortic stenosis: a propensity score-matched case-control study. *Am Heart J* 2012;164:910-917.
7. Yamamoto M, Meguro K, Mouillet G, Bergoend E, Monin JL, Lim P, Dubois-Rande JL, Teiger E. Comparison of effectiveness and safety of transcatheter aortic valve implantation in patients aged ≥ 90 years versus < 90 years. *Am J Cardiol* 2012;110:1156-1163.
8. Wendler O, Walther T, Schroefel H, Lange R, Treede H, Fusari M, Rubino P, Thomas M. Transapical aortic valve implantation: mid-term outcome from the SOURCE registry. *Eur J Cardiothorac Surg* 2013;43:505-511; discussion 511-502.
9. Wendler O, Thielmann M, Schroefel H, Rastan A, Treede H, Wahlers T, Eichinger W, Walther T. Worldwide experience with the 29-mm Edwards SAPIEN XT transcatheter heart valve in patients with large aortic annulus. *Eur J Cardiothorac Surg* 2013;43:371-377.
10. Kempfert J, Treede H, Rastan AJ, Schonburg M, Thielmann M, Sorg S, Mohr FW, Walther T. Transapical aortic valve implantation using a new self-expandable bioprosthesis (ACURATE TA): 6-month outcomes. *Eur J Cardiothorac Surg* 2013;43:52-56; discussion 57.
11. Van Mieghem NM, van der Boon RM, Nuis RJ, Schultz C, van Geuns RJ, Serruys PW, Kappetein AP, van Domburg RT, de Jaegere PP. Cause of death after transcatheter aortic valve implantation. *Catheter Cardiovasc Interv* 2014;83:E277-282.
12. Doss M, Buhr EB, Martens S, Moritz A, Zierer A. Transcatheter-based aortic valve implantations at midterm: what happened to our initial patients? *Ann Thorac Surg* 2012;94:1400-1406.
13. Ducrocq G, Al-Attar N, Himbert D, Messika-Zeitoun D, Iung B, Descoutures F, Nataf P, Vahanian A. Early and mid-term outcomes in patients undergoing transcatheter aortic valve implantation after previous coronary artery bypass grafting. *Eur J Cardiothorac Surg* 2012;41:499-504.
14. Ussia GP, Barbanti M, Petronio AS, Tarantini G, Etori F, Colombo A, Violini R, Ramondo A, Santoro G, Klugmann S, Bedogni F, Maisano F, Marzocchi A, Poli A, De Carlo M, Napodano M, Fiorina C, De Marco F, Antonucci D, de Cillis E, Capodanno D, Tamburino C. Transcatheter aortic valve implantation: 3-year outcomes of self-expanding CoreValve prosthesis. *Eur Heart J* 2012;33:969-976.
15. D'Onofrio A, Rubino P, Fusari M, Salvador L, Musumeci F, Rinaldi M, Vitali EO, Glauber M, Di Bartolomeo R, Alfieri OR, Polesel E, Aiello M, Casabona R, Livi U, Grossi C, Cassese M, Pappalardo A, Gherli T, Stefanelli G, Faggian GG, Gerosa G. Clinical and hemodynamic outcomes of "all-comers" undergoing transapical aortic valve implantation: results from the Italian Registry of Trans-Apical Aortic Valve Implantation (I-TA). *J Thorac Cardiovasc Surg* 2011;142:768-775.
16. Bosmans JM, Kefer J, De Bruyne B, Herijgers P, Dubois C, Legrand V, Verheye S, Rodrigus I. Procedural, 30-day and one year outcome following CoreValve or Edwards transcatheter aortic valve implantation: results of the Belgian national registry. *Interact Cardiovasc Thorac Surg* 2011;12:762-767.
17. Hernandez-Antolin RA, Garcia E, Sandoval S, Almeria C, Cuadrado A, Serrano J, de Obeso E, Del Valle R, Banuelos C, Alfonso F, Guerrero F, Heredia J, Martin Benitez JC, Garcia-Rubira JC, Rodriguez E, Macaya C. Findings of a Mixed Transfemoral Aortic

Valve Implantation Program Using Edwards and CoreValve Devices. *Rev Esp Cardiol (Engl Ed)* 2011;64:35-42.

18. Johansson M, Nozohoor S, Kimblad PO, Harnek J, Olivecrona GK, Sjogren J. Transapical versus transfemoral aortic valve implantation: a comparison of survival and safety. *Ann Thorac Surg* 2011;91:57-63.

19. Lefevre T, Kappetein AP, Wolner E, Nataf P, Thomas M, Schachinger V, De Bruyne B, Eltchaninoff H, Thielmann M, Himbert D, Romano M, Serruys P, Wimmer-Greinecker G. One year follow-up of the multi-centre European PARTNER transcatheter heart valve study. *Eur Heart J* 2011;32:148-157.

20. Leon MB, Smith CR, Mack M, Miller DC, Moses JW, Svensson LG, Tuzcu EM, Webb JG, Fontana GP, Makkar RR, Brown DL, Block PC, Guyton RA, Pichard AD, Bavaria JE, Herrmann HC, Douglas PS, Petersen JL, Akin JJ, Anderson WN, Wang D, Pocock S. Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. *N Engl J Med* 2010;363:1597-1607.

21. Drews T, Pasic M, Buz S, Unbehaun A, Dreysse S, Kukucka M, Mladenow A, Hetzer R. Transapical aortic valve implantation after previous heart surgery. *Eur J Cardiothorac Surg* 2011;39:625-630.

22. Attias D, Himbert D, Ducrocq G, Detaint D, Al-Attar N, Iung B, Francis F, Maury JM, Brochet E, Enguerrand D, Nataf P, Vahanian A. Immediate and mid-term results of transfemoral aortic valve implantation using either the Edwards Sapien transcatheter heart valve or the Medtronic CoreValve System in high-risk patients with aortic stenosis. *Arch Cardiovasc Dis* 2010;103:236-245.

23. Ye J, Cheung A, Lichtenstein SV, Nietlispach F, Albugami S, Masson JB, Thompson CR, Munt B, Moss R, Carere RG, Jamieson WR, Webb JG. Transapical transcatheter aortic valve implantation: follow-up to 3 years. *J Thorac Cardiovasc Surg* 2010;139:1107-1113. e1101.

24. Guinot PG, Depoix JP, Etchegoyen L, Benbara A, Provenchere S, Dilly MP, Philip I, Enguerand D, Ibrahim H, Vahanian A, Himbert D, Al-Attar N, Nataf P, Desmots JM, Montravers P, Longrois D. Anesthesia and perioperative management of patients undergoing transcatheter aortic valve implantation: analysis of 90 consecutive patients with focus on perioperative complications. *J Cardiothorac Vasc Anesth* 2010;24:752-761.

25. Avanzas P, Munoz-Garcia AJ, Segura J, Pan M, Alonso-Briales JH, Lozano I, Moris C, de Lezo JS, Hernandez-Garcia JM. Percutaneous Implantation of the CoreValve((R)) Self-Expanding Aortic Valve Prosthesis in Patients With Severe Aortic Stenosis: Early Experience in Spain. *Rev Esp Cardiol (Engl Ed)* 2010;63:141-148.

26. Kapadia SR, Goel SS, Svensson L, Roselli E, Savage RM, Wallace L, Sola S, Schoenhagen P, Shishehbor MH, Christofferson R, Halley C, Rodriguez LL, Stewart W, Kalahasti V, Tuzcu EM. Characterization and outcome of patients with severe symptomatic aortic stenosis referred for percutaneous aortic valve replacement. *J Thorac Cardiovasc Surg* 2009;137:1430-1435.

27. Walther T, Falk V, Borger MA, Kempfert J, Ender J, Linke A, Schuler G, Mohr FW. Transapical aortic valve implantation in patients requiring redo surgery. *Eur J Cardiothorac Surg* 2009;36:231-234; discussion 234-235.

28. Webb JG, Pasupati S, Humphries K, Thompson C, Altwegg L, Moss R, Sinhal A, Carere RG, Munt B, Ricci D, Ye J, Cheung A, Lichtenstein SV. Percutaneous transarterial aortic valve replacement in selected high-risk patients with aortic stenosis. *Circulation* 2007;116:755-763.